NO20002904L - (E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt - Google Patents

(E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt

Info

Publication number
NO20002904L
NO20002904L NO20002904A NO20002904A NO20002904L NO 20002904 L NO20002904 L NO 20002904L NO 20002904 A NO20002904 A NO 20002904A NO 20002904 A NO20002904 A NO 20002904A NO 20002904 L NO20002904 L NO 20002904L
Authority
NO
Norway
Prior art keywords
methoxy
monoagrinin
carboxylphenyl
dihydrobenzofuran
pyrazol
Prior art date
Application number
NO20002904A
Other languages
English (en)
Other versions
NO20002904D0 (no
Inventor
Joseph Robert Flisak
Albert Stephen Kearney
Nagesh Palepu
Cherng-Yih Perng
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20002904D0 publication Critical patent/NO20002904D0/no
Publication of NO20002904L publication Critical patent/NO20002904L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20002904A 1997-12-08 2000-06-07 (E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt NO20002904L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6773297P 1997-12-08 1997-12-08
PCT/US1998/025903 WO1999029685A1 (en) 1997-12-08 1998-12-07 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2-[(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt

Publications (2)

Publication Number Publication Date
NO20002904D0 NO20002904D0 (no) 2000-06-07
NO20002904L true NO20002904L (no) 2000-06-07

Family

ID=22078027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002904A NO20002904L (no) 1997-12-08 2000-06-07 (E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt

Country Status (24)

Country Link
US (1) US6300359B1 (no)
EP (1) EP1037888B1 (no)
JP (1) JP2001525405A (no)
KR (1) KR20010040292A (no)
CN (1) CN1281447A (no)
AR (1) AR017426A1 (no)
AT (1) ATE223404T1 (no)
AU (1) AU747108B2 (no)
BR (1) BR9813409A (no)
CA (1) CA2312965A1 (no)
CO (1) CO5021171A1 (no)
DE (1) DE69807745T2 (no)
DK (1) DK1037888T3 (no)
ES (1) ES2182383T3 (no)
HU (1) HUP0100423A3 (no)
IL (1) IL136592A (no)
NO (1) NO20002904L (no)
NZ (1) NZ504898A (no)
PL (1) PL341601A1 (no)
PT (1) PT1037888E (no)
TR (1) TR200001633T2 (no)
TW (1) TW505643B (no)
WO (1) WO1999029685A1 (no)
ZA (1) ZA9811154B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
WO2007067779A2 (en) * 2005-12-08 2007-06-14 Tsrl, Inc. Methods and compositions for drug delivery enhancement
TWI448301B (zh) * 2007-11-05 2014-08-11 Ala Wai Pharma Inc 用於增強經口投與之極性劑的生物可用性之調配物
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
AU2019242906A1 (en) 2018-03-29 2020-10-15 Nevro Corp. Leads having sidewall openings, and associated systems and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
CA2228293A1 (en) * 1995-08-02 1997-02-13 John Duncan Elliott Endothelin receptor antagonists

Also Published As

Publication number Publication date
AR017426A1 (es) 2001-09-05
NZ504898A (en) 2002-11-26
BR9813409A (pt) 2000-10-10
TR200001633T2 (tr) 2001-07-23
HUP0100423A2 (hu) 2002-05-29
CN1281447A (zh) 2001-01-24
AU1713899A (en) 1999-06-28
AU747108B2 (en) 2002-05-09
ES2182383T3 (es) 2003-03-01
ATE223404T1 (de) 2002-09-15
DK1037888T3 (da) 2003-01-06
TW505643B (en) 2002-10-11
EP1037888B1 (en) 2002-09-04
US6300359B1 (en) 2001-10-09
CA2312965A1 (en) 1999-06-17
KR20010040292A (ko) 2001-05-15
EP1037888A4 (en) 2001-08-22
DE69807745D1 (de) 2002-10-10
ZA9811154B (en) 1999-06-08
EP1037888A1 (en) 2000-09-27
NO20002904D0 (no) 2000-06-07
PT1037888E (pt) 2002-12-31
DE69807745T2 (de) 2003-05-15
IL136592A (en) 2003-03-12
PL341601A1 (en) 2001-04-23
CO5021171A1 (es) 2001-03-27
HUP0100423A3 (en) 2002-08-28
JP2001525405A (ja) 2001-12-11
HK1032229A1 (en) 2001-07-13
WO1999029685A1 (en) 1999-06-17
IL136592A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
MA25635A1 (fr) Essai immunologique pour les insecticides neonicotinyles
DK1224180T3 (da) Substituerede azoler
NO20016128D0 (no) Subsituerte heterocykliske fuserte gamma-karboliner
ATE357097T1 (de) Automatisches wiederholungsaufforderungsprotokoll
FR2832292B3 (fr) Collier pour animal de compagnie
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
MX9906600A (es) 4-(3-heterociclil-1-benzoil)pirazoles
NO20001260D0 (no) Optisk kommunikasjonssystem
NO20032452D0 (no) Aryletersubstituerte imidazolkinoliner
DE50014679D1 (de) Substituierte indol-mannichbasen
IS5715A (is) Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
PT1173435E (pt) Polimorfo de 5-¬4-¬2-(n-metil-n-(2-piridil)-amino)-etoxi|benzil|tiazolidino-2,4-diona sal de acido maleico
ATE308519T1 (de) 2,3-substituierte indolverbindungen als cox-2 inhibitoren
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
NO20002904D0 (no) (E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt
DE60017076D1 (de) Lasersystem
ID29138A (id) Metode untuk pelacakan data
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
NO20003611D0 (no) Optisk kommunikasjonssystem
IS5166A (is) Kristallað vatnað natríumsalt af (E)-4,6-díklóró-3-(2-oxó-1-fenýlpýrrólidín-3-ýliden metýl)-1h-indól-2-karboxýlsýru
DE59807563D1 (de) Substituierte 2-(3-alkenyl-benzoyl)-cyclohexan-1,3-dione
FR2782174B1 (fr) Assistance au pilotage stereoscopique
SI1037888T1 (en) (e)-3-(1-n-butyl- 5-(2-(2-carboxyphenyl)methoxy- 4-chlorophenyl)-1h- pyrazol-4-yl)-2- ((5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl)- prop-2-enoic acid monoargininyl salt
ATE272624T1 (de) Substituierte 4-(3-alkenyl-benzoyl)-pyrazole
TR199801735A3 (tr) 2-(arilfenil)amino-imidazolin türevleri.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application